Brief: Nasus Pharma Announces Positive Top Line Data From Phase 2 Clinical Study Of Ns002 Achieves Significantly Superior And Faster Epinephrine Delivery Compared To Epipen® With Accelerated Speed To Therapeutic Threshold
16/03/2026 11:38
March 16 (Reuters) - Nasus Pharma Ltd NSRX.A: NASUS PHARMA ANNOUNCES POSITIVE TOP LINE DATA FROM PHASE 2 CLINICAL STUDY OF NS002: ACHIEVES SIGNIFICANTLY SUPERIOR AND FASTER EPINEPHRINE DELIVERY COMPARED TO EPIPEN® WITH ACCELERATED SPEED TO THERAPEUTIC THRESHOLD NASUS PHARMA LTD - NS002 SHOWS FAVORABLE SAFETY PROFILE WITH NO SERIOUS ADVERSE EVENTS NASUS PHARMA LTD - NS002 ACHIEVES MEDIAN T100 OF 1.69 MINUTES VERSUS 3.42 MINUTES FOR EPIPEN NASUS PHARMA LTD - PIVOTAL STUDY INITIATION PLANNED FOR Q4 2026 NASUS PHARMA LTD - NS002 REACHES MEDIAN PEAK CONCENTRATION IN 15 MINUTES VERSUS 19.8 MINUTES FOR EPIPEN Source text: ID:nGNX61pzD2 Further company coverage: NSRX.A ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Nasus Pharma
See all newsBrief: Nasus Pharma Appoints Pharmaceutical Industry Veteran Brendan P. O'grady As Chief Executive Officer To Lead Strategic Growth
Brief: Nasus Pharma Announces Positive Top Line Data From Phase 2 Clinical Study Of Ns002 Achieves Significantly Superior And Faster Epinephrine Delivery Compared To Epipen® With Accelerated Speed To Therapeutic Threshold
Brief: Nasus Pharma Announces Closing Of $15.0 Million Private Placement
Brief: Nasus Pharma Strengthens Leadership Team, Appointing Eyal Rubin As Executive Vice President And Chief Financial Officer
Brief: Nasus Pharma Announces Initiation Of Phase 2 Clinical Study Of Ns002 With First Participant Dosed